Signaling pathways and immune evasion mechanisms in classical Hodgkin lymphoma
- 8 December 2017
- journal article
- review article
- Published by American Society of Hematology in Hematology
- Vol. 2017 (1), 310-316
- https://doi.org/10.1182/asheducation-2017.1.310
Abstract
Classical Hodgkin lymphoma (cHL) is an unusual B-cell–derived malignancy in which rare malignant Hodgkin and Reed-Sternberg (HRS) cells are surrounded by an extensive but ineffective inflammatory/immune cell infiltrate. This striking feature suggests that malignant HRS cells escape immunosurveillance and interact with immune cells in the cancer microenvironment for survival and growth. We previously found that cHLs have a genetic basis for immune evasion: near-uniform copy number alterations of chromosome 9p24.1 and the associated PD-1 ligand loci, CD274/PD-L1 and PDCD1LG2/PD-L2, and copy number–dependent increased expression of these ligands. HRS cells expressing PD-1 ligands are thought to engage PD-1 receptor–positive immune effectors in the tumor microenvironment and induce PD-1 signaling and associated immune evasion. The genetic bases of enhanced PD-1 signaling in cHL make these tumors uniquely sensitive to PD-1 blockade.Keywords
This publication has 60 references indexed in Scilit:
- Topological analysis reveals a PD-L1-associated microenvironmental niche for Reed-Sternberg cells in Hodgkin lymphomaBlood, 2017
- Phase II Study of the Efficacy and Safety of Pembrolizumab for Relapsed/Refractory Classic Hodgkin LymphomaJournal of Clinical Oncology, 2017
- T cell costimulatory receptor CD28 is a primary target for PD-1–mediated inhibitionScience, 2017
- Classical Hodgkin Lymphoma with Reduced β2M/MHC Class I Expression Is Associated with Inferior Outcome Independent of 9p24.1 StatusCancer Immunology Research, 2016
- Mutant MHC class II epitopes drive therapeutic immune responses to cancerNature, 2015
- PD-1 blockade induces responses by inhibiting adaptive immune resistanceNature, 2014
- Programmed cell death 1 forms negative costimulatory microclusters that directly inhibit T cell receptor signaling by recruiting phosphatase SHP2The Journal of Experimental Medicine, 2012
- Integrative analysis reveals selective 9p24.1 amplification, increased PD-1 ligand expression, and further induction via JAK2 in nodular sclerosing Hodgkin lymphoma and primary mediastinal large B-cell lymphomaBlood, 2010
- The role of cytokines in classical Hodgkin lymphomaBlood, 2002
- Genomic imbalances including amplification of the tyrosine kinase gene JAK2 in CD30+ Hodgkin cells.2000